Is there a role for salvage lymphadenectomy as second-line therapy post-robotic radical prostatectomy?

Goonewardene, Sanchia S.; Cahill, Declan

doi:10.1007/s00345-016-1816-4

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One-third will be free of biochemical relapse for 5 years [8]. Overall, it was felt that patients with a PSA value <4 ng/ml, low-intermediate risk cancer and clinical small volume LN relapse limited to the pelvis may benefit the most [7,33,36]. Despite the encouraging results mentioned above, the other retrospective study with 43 hormone-naive men who received transperitoneal sLND showed that transperitoneal sLND is neither an appropriate treatment to cure nor an option to delay the need for salvage hormone manipulation for most hormone-naïve men with a nodal recurrence of prostate cancer.…”

Section: Follow-up Outcomesmentioning

confidence: 99%

Salvage Lymphadenectomy as a Treatment of Prostate Cancer Recurrence

Xie¹,

LU²,

Gu³

et al. 2021

GSCR

View full text Add to dashboard Cite

Biochemical recurrence (BCR) occurs up to 40% of men who had radical prostatectomy for localized prostate cancer. Regional nodes are usually involved in these cases. Salvage lymphadenectomy (sLND) has been advocated in patients with 'node-only' metastasis with biochemical recurrence, following a definitive treatment of primary prostate cancer. In general, limited case number was reported for each previous study. Four relatively larger reports so far with the highest case number of 189. One randomized controlled study has been completed so far at Phase II level. Salvage LND seems to be safe with relatively low incidence of complications without perioperative mortality. It may postpone adjuvant therapy in selected cases, avoiding systemic side effects and possibly reducing the cost. However, long-term outcome is not very encouraging.

show abstract